Centene at Deutsche Bank summit: steady guidance, margin focus
Centene Corporation reiterated its 2026 adjusted diluted earnings guidance of more than $4.80 at the Deutsche Bank 2026 Healthcare Summit, indicating steady trends across its businesses and a focus on margins over growth. The company addressed challenges like Medicaid eligibility changes and Medicare Advantage reform, but stated it is on track with expectations and appears undervalued. Centene executives also discussed leadership transition plans, with CFO Drew Asher set to remain until the end of 2027 before Chris Neczypor takes over on January 1, 2028.
Cantor Fitzgerald reiterates Molina Healthcare stock rating at neutral By Investing.com
Cantor Fitzgerald has reiterated a neutral stock rating for Molina Healthcare Inc. (NYSE:MOH) with a price target of $209.00, noting the stock trades 4% below this target and appears undervalued by InvestingPro. The firm expressed optimism regarding the 2027 Stars ratings, citing lighter-than-expected movement in cutpoints, which could benefit several healthcare companies. Despite Molina's strong 36% return over the past six months and a "GOOD" financial health score, the neutral rating is maintained due to challenges in meeting 2029 targets and pressures from underperforming state D-SNP contracts, even as the company recently surpassed Q2 2026 earnings per share estimates.
Cantor Fitzgerald reiterates Molina Healthcare stock rating at neutral
Cantor Fitzgerald reiterated a neutral stock rating for Molina Healthcare Inc. (NYSE:MOH) with a price target of $209.00, noting the stock trades just 4% below this target. The firm expressed optimism regarding the 2027 Stars ratings release and believes concerns around UnitedHealth Group Inc. are misplaced. Despite strong recent performance and positive Q2 2026 results, challenges in reaching 2029 targets and underperformance in certain state contracts contribute to the maintained neutral rating.
Cantor Fitzgerald reiterates Neutral rating on Humana stock By Investing.com
Cantor Fitzgerald has reiterated a Neutral rating on Humana Inc. (NYSE:HUM) with a $300.00 price target, despite the stock trading significantly higher at $400.73 after a 136% surge. The firm expressed optimism about Humana's 2027 Stars ratings, citing accelerated program investments and finding that only 47% of 4-Star thresholds became more difficult. This analysis contributes to underwriting the Medicare Advantage margin and pricing cycle, aligning with other analysts' positive outlooks on Humana's earnings recovery.
Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2
This article analyzes the Q2 earnings season for health insurance providers, highlighting Progyny (NASDAQ:PGNY) as having the weakest guidance update despite a revenue beat. It contrasts Progyny's performance with other companies like CVS Health, Molina Healthcare, Alignment Healthcare, and Clover Health, detailing their Q2 results. The article also touches upon broader industry challenges and tailwinds, including regulatory scrutiny, AI's impact, and changing market concerns from AI to geopolitics.
Cantor Fitzgerald reiterates Molina Healthcare stock rating at Neutral
Cantor Fitzgerald has reiterated its Neutral rating on Molina Healthcare (NYSE:MOH) stock, despite the shares climbing 35% in the last six months. The firm noted that while the stock appears undervalued by InvestingPro analysis, small state D-SNP contracts underperformance and specific CMS nonpayment mechanisms pose challenges. The rating comes after Molina Healthcare reported strong Q2 2026 results, although Bernstein SocGen Group lowered its price target due to a weaker Marketplace outlook, and Cantor Fitzgerald maintained its Neutral stance citing concerns about meeting future targets.
Cantor Fitzgerald reiterates Molina Healthcare stock rating at Neutral By Investing.com
Cantor Fitzgerald has reiterated a Neutral rating on Molina Healthcare (NYSE:MOH) stock, despite the company's shares climbing 35% over the past six months and second-quarter 2026 results exceeding expectations. The firm cited underperformance in small, deconsolidated state D-SNP contracts and challenges in meeting future targets as reasons for maintaining the rating. Analysts have also revised earnings expectations downward, and while Molina is exiting MAPD in 2027, the firm provided no price target change.
Cantor Fitzgerald reiterates Molina Healthcare stock rating at Neutral By Investing.com
Cantor Fitzgerald has reiterated a Neutral rating on Molina Healthcare (NYSE:MOH) stock, despite the company's shares climbing 35% over the past six months. While Molina Healthcare reported strong Q2 2026 earnings that exceeded expectations, analysts have revised earnings expectations downward and cited challenges in meeting future targets. Bernstein SocGen Group also adjusted its price target lower due to a weaker Marketplace outlook, highlighting ongoing concerns about the company's future performance.
Molina Healthcare Announces Third Quarter 2026 Earnings Release and Conference Call Dates
Molina Healthcare (NYSE: MOH) announced it will release its third-quarter 2026 earnings after market close on October 21, 2026. The company will then host a conference call and webcast on October 22, 2026, at 8:00 a.m. Eastern Time to discuss these results. Details for accessing the live call, replay, and webcast are provided for investors.
Molina Healthcare Announces Third Quarter 2026 Earnings Release and Conference Call Dates
Molina Healthcare, Inc. (NYSE: MOH) announced it will release its third-quarter 2026 earnings on Wednesday, October 21, 2026, after market close. The company will host a conference call and webcast to discuss these results on Thursday, October 22, 2026, at 8:00 a.m. Eastern Time. Access details for the call and webcast replay have been provided.
Molina Healthcare (MOH) Q4 2025 Earnings: Results, Market Reaction & History
Molina Healthcare (MOH) reported a significantly disappointing Q4 2025 with an adjusted loss of $2.75 per share, largely due to unfavorable retroactive Medicaid premium adjustments and surging medical costs. Despite revenue beating estimates, the substantial earnings miss led to a 28% stock drop and price target reductions from analysts. The company provided 2026 guidance, expecting a trough for Medicaid margins and projecting embedded new-store earnings to materialize between 2027 and 2029.
Molina Healthcare stock holds near $200 after July earnings beat
Molina Healthcare stock maintained its position near $200 on August 31, 2026, following its July 22 earnings report which surpassed analyst expectations for both EPS and revenue. Despite beating estimates, the company experienced a year-over-year revenue decline of 4.8% and a negative net margin. The stock currently trades in the middle of its 52-week range, with analysts anticipating $5.29 EPS for the full year.
Molina Healthcare stock trades close to analyst target after weak Q2 2026 earnings
Molina Healthcare's stock is trading near its analyst consensus price target following a weak Q2 2026 earnings report and cautious full-year guidance. The company experienced a decline in revenue and a sharp drop in adjusted earnings per share due to higher medical costs and customer losses. Analysts have revised down their earnings estimates, viewing the stock as fairly valued despite its premium valuation compared to industry averages.
Mara Holdings CFO Salman Khan sells $147,360 in company stock
Salman Khan, CFO of MARA Holdings, Inc., sold 16,000 shares of company stock for $147,360 on August 17, 2026, pursuant to a Rule 10b5-1 trading plan adopted in September 2025. Following the sale, Mr. Khan retains a substantial direct and indirect holding in the company. This news comes as Marathon Digital Holdings reported a significant net loss in Q2 2026, though Guggenheim maintained a Neutral rating on the company.
Molina Healthcare stock trades near consensus target as Q2 2026 earnings underpin valuation
Molina Healthcare's stock is trading near Wall Street's consensus price target, supported by strong Q2 2026 earnings and institutional inflows. Despite a premium valuation and medical cost pressures, the company's robust cash generation, efficiency gains, and strategic contract renewals in government-sponsored programs (Medicaid, Medicare, Marketplace) are reinforcing investor confidence. The stock's performance hinges on continued disciplined medical cost management and execution of its growth strategy.
Molina Healthcare Insiders Sell US$3.6m Of Stock, Possibly Signalling Caution
Molina Healthcare insiders have sold US$3.6 million worth of stock over the last year, with no insider purchases recorded. This selling activity, particularly by President and CEO Joseph Zubretsky, could suggest that insiders believe the stock is fully valued or may face future headwinds. While insider selling isn't always a negative indicator, a significant amount without corresponding buying often warrants attention from potential investors.
Why Is Humana (HUM) Up 7.1% Since Last Earnings Report?
Humana (HUM) shares have risen 7.1% since its last earnings report, outperforming the S&P 500, following a strong Q2 2026 performance. The company reported adjusted earnings of $7.61 per share, beating estimates by 22.4%, and revenues of $40.9 billion, a 26.2% year-over-year increase, driven by premium gains and robust growth in its CenterWell segment. Despite increased operating expenses and a deteriorating benefit ratio, Humana's medical membership growth and improved operating cost ratio contributed to its positive results.
Molina Healthcare (MOH) Q1 2025 Earnings: Results, Market Reaction & History
Molina Healthcare reported strong Q1 2025 earnings, surpassing analyst expectations with adjusted EPS of $6.08 and revenue of $11.15 billion, driven by new contract wins and acquisitions. The company reaffirmed its full-year 2025 guidance and expressed confidence in achieving its long-term adjusted EPS growth target of 13% to 15%, fueled by embedded earnings from newly awarded contracts and recent acquisitions. Key drivers included significant growth in premium revenue and Marketplace membership, alongside disciplined medical cost management.
Why Molina Healthcare (MOH) Is Back In The Spotlight
Molina Healthcare (MOH) is gaining attention due to recent stock momentum, with a 0.6% gain over the past day and a double-digit rise over the last three months, despite longer-term declines. The stock is considered 4.5% undervalued with a fair value of $209.12, driven by successful RFP wins in Nevada and Illinois expected to boost revenue and EPS. However, potential risks include reductions in Medicaid funding or changes in marketplace subsidies.
Molina Healthcare Inc. stock underperforms Thursday when compared to competitors
Molina Healthcare Inc. (MOH) stock declined by 1.82% on Thursday, closing at $198.75, despite a generally positive trading session for the broader market. This underperformance occurred as the S&P 500 Index rose 0.72% and the Dow Jones Industrial Average increased by 0.20%. The stock's fall ended a two-day winning streak for Molina Healthcare.
Molina Healthcare stock trades close to analyst target as earnings estimates adjust
Molina Healthcare stock is trading near $200, close to analysts' consensus target of $202.44, despite 2026 being projected as a trough year for earnings. While recent quarterly results showed a modest beat on EPS and revenue, the company faces top-line headwinds and a worsening medical-cost ratio. Investors are weighing the current valuation against the potential for earnings recovery to normalized levels in future periods.
Molina Healthcare, Inc. (MOH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Molina Healthcare, Inc. (MOH) concerning potential corporate wrongdoing. The firm is encouraging investors who purchased Molina securities prior to February 5, 2025, and continue to hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis, seeking reimbursement only if successful.
Molina Healthcare stock trades close to consensus target as earnings expectations firm
Molina Healthcare Inc. (MOH) stock is trading near its consensus price target, driven by strong 2026 premium revenue guidance of $42 billion and earnings expectations of $5.29 per share. The company's focus on government-sponsored health plans and a membership base of 4.9 million members underscore its growth trajectory, despite a mixed track record on earnings surprises and a recent legal settlement that had minimal financial impact. The current stock price of $203.44 is slightly above the $202.44 consensus target, indicating the market's balanced view of its risks and opportunities.
Zacks Industry Outlook UnitedHealth, The Cigna, Humana, Centene and Molina
The U.S. health insurance industry, particularly Health Maintenance Organizations (HMOs), is experiencing growth due to a diversified membership base, an aging population, digital transformation, and strategic M&A. Key players like UnitedHealth, Cigna, Humana, Centene, and Molina are well-positioned to capitalize on these trends. The industry is also benefiting from increased Medicare Advantage enrollment, technology investments for efficiency, and strategic acquisitions to broaden services.
Zacks Industry Outlook UnitedHealth, The Cigna, Humana, Centene and Molina
The U.S. health insurance industry, particularly Health Maintenance Organizations (HMOs), is experiencing growth due to a diversified membership, an aging population, digital transformation, and strategic mergers and acquisitions. Industry leaders like UnitedHealth Group, Cigna, Humana, Centene, and Molina Healthcare are well-positioned to capitalize on these trends. The sector shows strong near-term prospects with a Zacks Industry Rank in the top 10% and has outperformed the S&P 500 and the broader Medical sector over the past year.
Resilient Molina Healthcare stock holds near consensus target as guidance for 2026 stays firm
Molina Healthcare stock is trading near analysts' consensus target after a strong second quarter in 2026. The company maintained its 2026 premium revenue guidance at $42 billion while raising both GAAP and adjusted earnings guidance. Despite a "Hold" consensus rating, institutional investors continue to show interest, with the stock positioned as a core holding for some sophisticated investors due to its focus on government-backed healthcare programs.
Bronstein, Gewirtz & Grossman, LLC Encourages Molina Healthcare, Inc. (MOH) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Molina Healthcare, Inc. (MOH) for alleged corporate wrongdoing. The firm encourages shareholders who purchased Molina securities before February 5, 2025, and still hold them, to contact them for more information and to assist with the investigation. The firm operates on a contingency fee basis, meaning no upfront costs for investors.
Molina Healthcare (MOH) Is Down 5.7% After Raising 2026 Earnings Guidance Amid Falling Membership - Has The Bull Case Changed?
Molina Healthcare (MOH) reported strong Q2 2026 results, surpassing earnings estimates and raising its full-year 2026 guidance despite a decline in total membership. This indicates improved operational efficiency and profitability. While the raised guidance is positive, investors should remain aware of risks related to government funding and contract changes, which are central to Molina's Medicaid and Marketplace focused investment narrative.
3 US Large Cap Stocks for Investors Seeking Alternatives to Crowded AI Trades
This article highlights three U.S. large-cap stocks — Cooper Companies (COO), Molina Healthcare (MOH), and CareTrust REIT (CTRE) — as alternatives for investors seeking to diversify away from crowded AI-related trades. These companies offer exposure to healthcare, vision care, fertility, and real estate, providing different growth drivers and risk profiles compared to the tech sector. The article details their operations, market caps, and potential upsides, while also noting associated risks for each.
AVOIDABLE: Molina Healthcare Settles TCPA Wrong Number Class Action For $1.93MM– and This Doesn’t Have to Keep Happening
Molina Healthcare has settled a TCPA class action lawsuit for $1.93 million, stemming from prerecorded wrong-number calls to cellular phones that were not assigned to Molina customers. The settlement highlights common pitfalls for companies making outbound calls, emphasizing the importance of not using "wrong number" dispositions for tracking and utilizing the Reassigned Numbers Database. The case involved calls to 18,794 class members, each receiving approximately $102.69, demonstrating that such costly lawsuits can be avoided with proper compliance strategies.
Molina Healthcare stock holds steady after stronger 2026 guidance
Molina Healthcare reported second-quarter 2026 adjusted EPS of $1.51, beating Zacks Consensus Estimate, and provided full-year adjusted EPS guidance of at least $5.25. While revenue declined year-over-year, the company raised its GAAP earnings and adjusted net income guidance, leading to its stock holding steady despite a "Hold" consensus. The company focuses on government-sponsored managed care, serving Medicaid, Medicare, and Marketplace members.
MOH5074366 Bond Profile — Key Metrics
This article provides a detailed profile of the MOH5074366 bond issued by Molina Healthcare, Inc. It outlines key financial metrics such as the coupon rate, issue and maturity dates, outstanding amount, and face value. The bond, a 3.875% bond maturing on November 15, 2030, is further contextualized with information about Molina Healthcare's business segments.
AVOIDABLE: Molina Healthcare Settles TCPA Wrong Number Class Action For $1.93MM– and This Doesn’t Have to Keep Happening
Molina Healthcare has settled a TCPA class action lawsuit for $1.93 million involving prerecorded calls made to wrong numbers. The settlement highlights the financial risks companies face due to improper handling of wrong numbers and reassigned numbers, even for non-marketing calls. The author suggests two key strategies to avoid such lawsuits: not using "wrong number" dispositions in records and consistently utilizing the reassigned numbers database for outbound campaigns.
Molina Healthcare Inc. stock outperforms competitors on strong trading day
Molina Healthcare Inc. (MOH) stock increased by 1.70% to $200.29 on Friday, outperforming the broader market. This rise snapped a two-day losing streak for the company. The S&P 500 Index (SPX) also rose by 0.43%, and the Dow Jones Industrial Average (DJIA) was up by 0.98%.
AVOIDABLE: Molina Healthcare Settles TCPA Wrong Number Class Action For $1.93MM– and This Doesn’t Have to Keep Happening
Molina Healthcare has settled a TCPA class action lawsuit for $1.93 million, stemming from prerecorded calls made to wrong numbers. The settlement highlights the financial risks companies face when making non-marketing calls to reassigned numbers and underscores the importance of using the Reassigned Numbers Database (RND) and avoiding problematic "wrong number" disposition tracking. The article emphasizes that such class actions are largely avoidable with proper protocols.
Silvant Capital Management LLC Makes New $5.32 Million Investment in Molina Healthcare, Inc $MOH
Silvant Capital Management LLC has made a new investment of $5.32 million in Molina Healthcare, Inc. (NYSE:MOH) by acquiring 23,245 shares. Other institutional investors have also adjusted their holdings in Molina Healthcare, with a significant portion of the stock now owned by institutional investors. Molina Healthcare's stock recently traded at $197.69, and the company reported earnings that beat analyst estimates in its last quarterly report.
6,572,156 Shares in Molina Healthcare, Inc $MOH Acquired by BlackRock Inc.
BlackRock Inc. has acquired 6,572,156 shares of Molina Healthcare, Inc. (NYSE:MOH) valued at approximately $1.50 billion, representing a 12.59% stake in the company. This acquisition makes BlackRock a significant institutional investor in Molina Healthcare, which recently reported Q2 earnings of $1.51 per share, exceeding estimates, despite a 4.8% year-over-year revenue decline. Analysts currently have a "Hold" rating on MOH with an average price target of $202.44.
Molina Healthcare Inc. stock underperforms Thursday when compared to competitors
Molina Healthcare Inc. (MOH) stock fell 2.10% on Thursday, closing at $196.94. This underperformance occurred during a generally negative trading session, with the S&P 500 Index and Dow Jones Industrial Average also experiencing declines. The stock recorded its second consecutive day of losses.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Molina Healthcare, Inc. (MOH) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Molina Healthcare, Inc. (MOH) for corporate wrongdoing. The firm is encouraging shareholders who purchased Molina securities before February 5, 2025, and still hold them, to connect and assist with the investigation. The investigation aims to restore investor capital and ensure corporate accountability, with no cost to Molina investors unless the firm is successful in court.
Tocqueville Asset Management L.P. Takes $22.67 Million Position in Quest Diagnostics Incorporated $DGX
Tocqueville Asset Management L.P. recently acquired a new stake of 106,964 shares, valued at $22.67 million, in Quest Diagnostics Incorporated (NYSE:DGX). This makes Tocqueville Asset Management L.P. one of several institutional investors to either boost or initiate positions in DGX. The article also details recent insider stock transactions, Quest Diagnostics' financial performance, dividend announcement, and updated analyst price targets.
Molina Healthcare stock holds above $200 as Q2 2026 guidance tempers earnings beat
Molina Healthcare's stock is holding above $200 after its Q2 2026 earnings beat was tempered by a softer revenue outlook, causing a slight dip from recent highs. Analysts largely view the stock as fairly valued, with its Medicaid segment continuing to drive profitability despite some investor concerns about future revenue growth. The company's ability to manage medical costs and maintain margin discipline remains key to sustaining its current valuation.
Molina Healthcare Inc. stock underperforms Wednesday when compared to competitors
Molina Healthcare Inc. (MOH) stock declined by 1.20% on Wednesday, closing at $201.17, despite a positive trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains. Molina Healthcare Inc. shares were also 17.85% below their 52-week high.
News roundup: UHS-Talkspace $850M buy final, DocGo to buy Hicuity Health for $52M in stock/debt, R1 to buy Humata Health, PointClickCare EHR to integrate Anthropic’s AI
Universal Health Services (UHS) has finalized its $835 million acquisition of Talkspace, integrating its virtual behavioral health services. DocGo is set to acquire Hicuity Health for $52 million in debt and stock, expanding into high acuity clinical care. R1 will acquire Humata Health to enhance its AI-powered revenue cycle management solutions, and PointClickCare will integrate Anthropic’s AI into its EHR platform for senior care.
Molina Healthcare of Michigan and the MSMS Foundation to Provide Shortage Area Scholarships
Molina Healthcare of Michigan and the Michigan State Medical Society (MSMS) Foundation are partnering to offer four $10,000 scholarships to students in healthcare training programs. These scholarships aim to address the shortage of healthcare professionals in underserved Michigan communities, with preference given to applicants committed to practicing in such areas. Eligible applicants must demonstrate financial need, academic promise, and a dedication to community-based care, with applications due by October 15, 2026.
Pallas Capital Advisors LLC Makes New $2.23 Million Investment in Molina Healthcare, Inc $MOH
Pallas Capital Advisors LLC has made a new investment of $2.23 million in Molina Healthcare, Inc., purchasing 9,746 shares during the second quarter. This move is part of a broader trend of institutional investors adjusting their positions in Molina Healthcare, with several firms increasing their stakes. The article also details recent analyst ratings, stock performance metrics, and the company's latest quarterly earnings.
Molina Healthcare, Inc (NYSE:MOH) Given Consensus Rating of "Hold" by Brokerages
Molina Healthcare, Inc (NYSE:MOH) has received a consensus "Hold" rating from 17 brokerages, with an average 12-month price target of $202.44. While some firms like Barclays and Truist Financial recently lowered their price targets, TD Cowen raised its target but maintained a "Hold" rating. The company reported better-than-expected quarterly EPS of $1.51, beating the $1.39 consensus, and revenues of $10.87 billion.
The MolinaCares Accord and Molina Healthcare of Michigan Donate $100,000 to Support Construction of a New Food Kitchen in Saginaw County
The MolinaCares Accord and Molina Healthcare of Michigan have donated $100,000 to the Saginaw Food Club and Kitchen to support the construction of a new facility. This donation aims to improve access to healthy, affordable food for local households, many of whom struggle to access healthy meals after exhausting their food benefits. The new Food Club will offer a low-cost, income-based membership program designed to incentivize healthy eating.
The MolinaCares Accord and Molina Healthcare of Michigan Donate $100,000 to Support Construction of a New Food Kitchen in Saginaw County
The MolinaCares Accord and Molina Healthcare of Michigan have donated $100,000 to the Saginaw Food Club and Kitchen to help construct a new facility in Saginaw County. This donation aims to improve access to healthy, affordable food for local households, particularly those at or below 200% of the federal poverty level. The new Food Club will offer a low-cost, income-based membership program where members can shop for groceries using a point system that incentivizes healthier food choices.
Why is Centene stock sliding today?
Centene Corp (CNC) stock dropped over 3% in morning trading after the announcement of CFO Drew Asher's planned departure and succession by Chris Neczypor. The leadership change comes at a sensitive time for Centene, which is undergoing a financial turnaround, causing investors to focus on potential continuity risks despite reaffirmed EPS guidance. The stock's recent rally to near its 52-week high also contributed to investor reassessment, with the broader market offering no buffer.
Oppenheimer Asset Management Inc. Makes New $1.43 Million Investment in HCA Healthcare, Inc. $HCA
Oppenheimer Asset Management Inc. has initiated a new position in HCA Healthcare, Inc. by purchasing 3,669 shares valued at approximately $1.43 million during the second quarter. HCA Healthcare reported strong quarterly results with revenue up 8.7% year-over-year to $20.23 billion and earnings exceeding analyst expectations. The company also declared a quarterly dividend of $0.78 per share, and analysts maintain a consensus "Moderate Buy" rating with an average price target of $465.59.
